GlassScriptPhysician profile
Margaret Irby
NPI 1689382202
$1,797.75
in general payments reported to CMS, 2019-2025
17 companies · $1,557 in 2025
The $1,557 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $241 · 2025: $1,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,797.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $328.17 | 2024-2025 | Acthar |
| Genzyme Corporation | $192.73 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $161.77 | 2025 | Tezspire |
| Grifols USA, LLC | $150.30 | 2024-2025 | Prolastin-C Liquid |
| Philips North America LLC | $149.70 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Vifor Pharma, INC. | $139.46 | 2025 | Zemaira |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.85 | 2025 | Ofev, Jascayd |
| Viatris Specialty LLC | $114.07 | 2025 | Yupelri |
| Glaxosmithkline, LLC. | $111.21 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $83.73 | 2025 | Glassia |
| Merck Sharp & Dohme LLC | $79.51 | 2024-2025 | Zerbaxa, Dificid |
| United Therapeutics Corporation | $41.84 | 2025 | Tyvaso |
| Harmony Biosciences LLC | $31.97 | 2025 | |
| Inspire Medical Systems, INC. | $24.22 | 2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $23.80 | 2025 | Opsynvi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $18.01 | 2025 | Zepbound |
| Boston Scientific Corporation | $14.41 | 2024 | Watchman Access System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Irby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.